tbuckley/cabot-search huggingface dataset:
Taxane sensitivity markers in prostate cancer.
Authors: Rebecca Feldman, Michael Castro, Sandeep K. Reddy, Charles E. Myers
Journal: Journal of Clinical Oncology (2016)

285 Background: The results from the CHAARTED and STAMPEDE trials that docetaxel plus androgen-deprivation therapy (ADT) significantly improves survival over ADT alone among men with metastatic, hormone-sensitive and hormone-naïve prostate cancers, represents a potential practice-changing movement. Clinical data exist to support the role of various predictive markers for taxane response, including low or negative class III beta tubulin (TUBB3), positive transducin-like enhancer of split 3 (TLE3) and low or negative p-glycoprotein (PGP/ABCB1). We examined a database of molecularly-profiled prostate cancer patients for taxane sensitivity markers for insight into the mechanism behind the clinical effect of docetaxel. Methods: 348 patients with prostate cancer were included in the study and tested centrally at a CLIA laboratory (Caris Life Sciences, Phoenix, AZ). Tests included one or more of the following: gene sequencing (Sanger or next generation sequencing [NGS]), protein expression (immunohistochemistry [IHC]) and gene amplification (C/FISH). Results: In all prostate cases tested, protein levels for taxane markers are: TLE3+ 58.6% (174/297), TUBB3 - 76.8% (228/297) and PGP – 89.9% (267/297). Combined rate of expression (TLE3+/TUBB3-/PGP-) is 41% (121/297), representing a subgroup of patients that may have best responses to taxane therapy. Taxane sensitivity markers by stage and AR status are shown in the table below. Conclusions: Taxane sensitivity markers are observed at a statistically significant higher frequency in AR-positive prostate cancer patients, providing a potential molecular hypothesis for the increased effectiveness of chemo-hormonal therapy observed in hormone-sensitive prostate cancers. A substantial number of both AR positive and negative patients have sub-optimal biomarker profile for taxane responsiveness highlighting an unmet need for on-going drug development in this disease. [Table: see text]
Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy
Authors: Zohar Shatsberg, Xuejiao Zhang, Paula Ofek, Shashwat Malhotra, Adva Krivitsky, Anna Scomparin, Galia Tiram, Marcelo Calderón, Rainer Haag, Ronit Satchi-Fainaro
Journal: Journal of Controlled Release (2016)
P1009 : Incidence of major cardiovascular and cerebral events in patients with NAFLD and in controls of general population during 10 years of follow up: correlation between vascular and liver damage
Authors: G. Pisano, S. Tiraboschi, R. Lombardi, C. Bertelli, L. Valenti, A. Baragetti, L. Grigore, M. Porzio, A. Catapano, S. Fargion, A.L. Fracanzani
Journal: Journal of Hepatology (2015)
Whole-Genome Sequencing and Acute Promyelocytic Leukemia—Reply
Authors: Peter Westervelt
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
3-Dimensional Printed Anatomic Models as Planning Aids in Complex Oncology Surgery
Authors: Jane S. Matsumoto, Jonathan M. Morris, Peter S. Rose
Journal: JAMA Oncology (2016)

This Viewpoint examines the results of a survey of 19 tumor surgeons regarding their experiences with oncologic 3-D models; surgeons were asked how helpful the models were or how likely the models were to improve care.
Adolescent Pregnancy: Incidence and Cost
Authors: Debra W. Haffner
Journal: JAMA (1987)

To the Editor.—  Articles by Blum, 1 Hamburg et al, 2 and Marks and Kreuter 3 in the June 26, 1987, issue ofTHE JOURNALall quote the Center for Population Options study on the public costs of teenage childbearing in 1985.  In May 1987, the Center for Population Options released its estimates for calendar year 1986. In that year, the United States spent $17.93 billion on all families that were begun when the mother was a teenager. This figure includes public outlays for Aid to Families With Dependent Children, Medicaid, and food stamps for families begun by a teen birth.  A family begun by a first birth to a teenage mother in 1986 will cost the taxpayer an average of $14 852 by the time that baby reaches age 20 years. All families begun by teen first births in 1986 will cost the United States $5.5 billion during the
Hidradenitis suppurativa: a disease of infundibular epidermis rather than pilosebaceous units?
Authors: I.C. Janse, J.L. Blok, G.F.H. Diercks, B. Horváth, M.F. Jonkman
Journal: British Journal of Dermatology (2016)

although the exact pathogenesis of hidradenitis suppurativa (HS) is unknown, it is established that it is primarily an infundibulitis.(1,2) We consider infundibulum as epidermis and not as hair follicle according to Ackerman, as the type of epithelial tissue of infundibular epidermis is indistinguishable from that of interfollicular epidermis.(1) This article is protected by copyright. All rights reserved.
Causes of Ferritin Elevation
Authors: Lisa B. VanWagner, Richard M. Green
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epigenetic Regulation: A New Frontier for Biomedical Engineers
Authors: Zhen Chen, Shuai Li, Shankar Subramaniam, John Y.-J. Shyy, Shu Chien
Journal: Annual Review of Biomedical Engineering (2017)

Gene expression in mammalian cells depends on the epigenetic status of the chromatin, including DNA methylation, histone modifications, promoter-enhancer interactions, and noncoding RNA-mediated regulation. The coordinated actions of these multifaceted regulations determine cell development, cell cycle regulation, cell state and fate, and the ultimate responses in health and disease. Therefore, studies of epigenetic modulations are critical for our understanding of gene regulation mechanisms at the molecular, cellular, tissue, and organ levels. The aim of this review is to provide biomedical engineers with an overview of the principles of epigenetics, methods of study, recent findings in epigenetic regulation in health and disease, and computational and sequencing tools for epigenetics analysis, with an emphasis on the cardiovascular system. This review concludes with the perspectives of the application of bioengineering to advance epigenetics and the utilization of epigenetics to translate bioengineering research into clinical medicine.
Erratum: Common variants at 12q15 and 12q24 are associated with infant head circumference
Authors: H Rob Taal, Beate St Pourcain, Elisabeth Thiering, Shikta Das, Dennis O Mook-Kanamori, Nicole M Warrington, Marika Kaakinen, Eskil Kreiner-Møller, Jonathan P Bradfield, Rachel M Freathy, Frank Geller, Mònica Guxens, Diana L Cousminer, Marjan Kerkhof, Nicholas J Timpson, M Arfan Ikram, Lawrence J Beilin, Klaus Bønnelykke, Jessica L Buxton, Pimphen Charoen, Bo Lund Krogsgaard Chawes, Johan Eriksson, David M Evans, Albert Hofman, John P Kemp, Cecilia E Kim, Norman Klopp, Jari Lahti, Stephen J Lye, George McMahon, Frank D Mentch, Martina Müller-Nurasyid, Paul F O'Reilly, Inga Prokopenko, Fernando Rivadeneira, Eric A P Steegers, Jordi Sunyer, Carla Tiesler, Hanieh Yaghootkar, Monique M B Breteler, Stéphanie Debette, Myriam Fornage, Vilmundur Gudnason, Lenore J Launer, Aad van der Lugt, Thomas H Mosley, Sudha Seshadri, Albert V Smith, Meike W Vernooij, Alexandra I F Blakemore, Rosetta M Chiavacci, Bjarke Feenstra, Julio Fernandez-Banet, Struan F A Grant, Anna-Liisa Hartikainen, Albert J van der Heijden, Carmen Iñiguez, Mark Lathrop, Wendy L McArdle, Anne Mølgaard, John P Newnham, Lyle J Palmer, Aarno Palotie, Annneli Pouta, Susan M Ring, Ulla Sovio, Marie Standl, Andre G Uitterlinden, H-Erich Wichmann, Nadja Hawwa Vissing, Charles DeCarli, Cornelia M van Duijn, Mark I McCarthy, Gerard H Koppelman, Xavier Estivill, Andrew T Hattersley, Mads Melbye, Hans Bisgaard, Craig E Pennell, Elisabeth Widen, Hakon Hakonarson, George Davey Smith, Joachim Heinrich, Marjo-Riitta Jarvelin, Vincent W V Jaddoe
Journal: Nature Genetics (2013)
Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
Authors: Eric Jay Small, Jack Youngren, George Thomas, Susan Olson, Alexandria Toschi, Adam Foye, Joshi J. Alumkal, Matthew Rettig, Martin Edwin Gleave, Christopher P. Evans, Josh Stuart, Charles J. Ryan, Robert Evan Reiter, Kim N. Chi, Primo Lara, Tomasz M. Beer
Journal: Journal of Clinical Oncology (2014)

5020 Background: The mechanisms of resistance to androgen signaling inhibitors such as Abiraterone (Abi) or Enzalutamide (Enz) are poorly understood. AR amplification (AR+) has been observed in Abi/Enz naive mCRPC patients (pts), but its role in Abi/Enz resistant pts is not known. Progressive mCRPC has historically been challenging to biopsy and characterize on a molecular basis because of its bone tropism. As part of the WCDT project which aims to identify genetic pathways underlying primary and acquired resistance to Abi and Enz, AR+ was assessed in mCRPC biopsies. Methods: Following central radiologic review, eligible mCRPC pts underwent biopsy at one of 5 WCDT clinical sites, using a uniform biopsy protocol. Tissue was both frozen, and formalin fixed/paraffin embedded (FFPE). FFPE tissue underwent a CLIA-certified assessment of a mutational panel, IHC for PTEN, and fluorescence in situ hybridization (FISH) for AR+. Results: 60 of 300 planned mCRPC pts have undergone a metastasis biopsy. To date, 33 pts have had biopsies successfully evaluated by AR FISH, including 12 from bone, 11 from lymph nodes, 8 from liver and 2 from other soft tissues. Of 16 Abi and Enz naive pts, 13 (81%) were AR+. By contrast, only 1/11 Abi resistant pts (9%) was AR+. 4/6 Enz resistant pts (67%) were AR+. Of 6 AR+ patients that went on to receive Abi or Enz, 3 (50%) had a response (PCWG2 criteria), whereas of 5 pts without AR+ who went on to receive Abi/Enz, just 1 (20%) had a response. Conclusions: AR amplification can be evaluated by FISH in small biopsies of mCRPC, including bone, and it was observed in 18/33 samples (55%). AR+ was common in mCRPC patients prior to therapy with Abi or Enz (81%). However, once resistance developed, Abi resistant pts had a far lower likelihood of AR+ (9%) than Enz resistant pts (67%). These data support the hypothesis that treatment with Abiraterone selects for non-AR amplified cells, whereas Enzalutamide does not. In this relatively small cohort, mCRPC pts with AR+ are more likely to respond to subsequent AR targeted therapeutics than pts without AR+.
Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion
Authors: Claudia Djambas Khayat, Johnny N. Mahlangu, Ross I Baker, Cindy A. Leissinger, Elena Santagostino, Debra M. Bensen-Kennedy, Katie St. Ledger, Alex Veldman, Ingrid Pabinger
Journal: Blood (2015)
Defining the Primate T Cell Transcriptome during Graft Versus Host Disease: New Data Implicating the Hedgehog and Aurora Kinase Pathways in Pathogenesis and Prevention
Authors: Scott N. Furlan, Benjamin Watkins, Ryan P Flynn, Swetha Ramakrishnan, Karnail Singh, Cynthia R. Giver, Kelly Hanby, Linda Stempora, Aneesah P. Garrett, Carly GK Ziegler, Gregory Tharp, Steven Bosinger, Bruce R. Blazar, Edmund K. Waller, Leslie S. Kean
Journal: Blood (2014)
Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood
Authors: Glynis Frans, Leen Moens, Heidi Schaballie, Greet Wuyts, Adrian Liston, Koen Poesen, Ann Janssens, Gillian I. Rice, Yanick J. Crow, Isabelle Meyts, Xavier Bossuyt
Journal: Journal of Allergy and Clinical Immunology (2016)
The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study
Authors: S.K. Grewal, J. Wan, M.R. Denburg, D.B. Shin, J. Takeshita, J.M. Gelfand
Journal: British Journal of Dermatology (2016)

Psoriasis, particularly when moderate to severe, is associated with an increased risk of incident chronic kidney disease (CKD)1, although specific renal diseases observed in psoriasis patients remain poorly defined. Of special interest is IgA nephropathy (IgAN), which presents with episodic macroscopic hematuria and can lead to CKD and end-stage kidney disease.

This article is protected by copyright. All rights reserved.
RETRACTED ARTICLE: HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail
Authors: Bo Tang, Guangying Qi, Xiaoyu Sun, Fang Tang, Shengguang Yuan, Zhenran Wang, Xingsi Liang, Bo Li, Shuiping Yu, Jie Liu, Qi Huang, Yangchao Wei, Run Zhai, Biao Lei, Xinjin Guo, Songqing He
Journal: Molecular Cancer (2016)

Liver cancer is one of the main causes of cancer-related death in human. HOXA7 has been proved to be related with several cancers.The expression levels of HOXA7 were examined by Western blot, qRT-PCR or ICH. MTT was used to detect the proliferative rate of liver cancer cells. The invasive abilities were examined by matrigel and transwell assay. The metastatic abilities of liver cancer cells were revealed in BALB/c nude mice.In this report, we revealed that HOXA7 promoted metastasis of HCC patients. First, increased levels of HOXA7 were examined in liver cancer especially in metastatic liver cancer. Moreover, higher expression level of HOXA7 was associated with poorer prognosis of liver cancer patients. Overexpression of HOXA7 significantly enhanced proliferation, migration, invasion in vitro and tumor growth and metastasis in vivo meanwhile silencing HOXA7 significantly inhibited the aboves abilities of liver cancer cells. In this research, we identified that HOXA7 performed its oncogenic characteristics through activating Snail.Collectively, we identify the critical role and possible mechanism of HOXA7 in metastasis of liver cancer which suggest that HOXA7 may be a potential therapeutic target of liver cancer patients.
Intermittent Androgen Deprivation Therapy—An Important Treatment Option for Prostate Cancer
Authors: Laurence Klotz, Celestia S, Higano
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Impact of Unbalanced Translocation Der(1;7)(q10;p10) and -7/Del(7q) on the Prognostic Value after Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Nationwide Retrospective Study
Authors: Hidehiro Itonaga, Kazunari Aoki, Jun Aoki, Ken Ishiyama, Takayuki Ishikawa, Kazuteru Ohashi, Takahiro Fukuda, Yukiyasu Ozawa, Naoki Kobayashi, Naoyuki Uchida, Tetsuya Eto, Minoko Takanashi, Tatsuo Ichinohe, Yoshiko Atsuta, Yasushi Miyazaki
Journal: Blood (2015)
Retrospective Analysis of 1230 Patients of Immune Thrombocytopenic Purpura Reporting to a Tertiary Care Hospital in India from 1992–2004.
Authors: Dharma R. Choudhary, Rajat Kumar, R. Saxena, Manoranjan Mahapatra, Atul Kotwal, H. P. Pati, Ashish Dixit, V. P. Choudhry
Journal: Blood (2004)
Dopamine vs Nesiritide for Acute Heart Failure With Renal Dysfunction
Authors: Sachin Kumar
Journal: JAMA (2014)

Dr Chen and colleagues1 evaluated the role of low-dose dopamine and nesiritide as individual strategies in treating patients with acute decongested heart failure while attempting to preserve or improve renal function. The trial found no benefit from low-dose dopamine or nesiritide with standard diuretic therapy. Despite significant advances in understanding the pathophysiology of acute heart failure, contemporary therapies have failed to have an effect.2
Do we overestimate the performance of the basket catheter for stone removal if the bile duct is swept with a balloon?
Authors: Abdurrahman Kadayifci, M. Savas
Journal: Endoscopy (2016)

We read with great interest the paper by Ishiwatari et al. published in the April issue of Endoscopy [1]. The authors compared the performance of balloon and basket catheters for the removal of bile duct stones (diameter ≤ 10 mm) during endoscopic retrograde cholangiopancreatography (ERCP) in a multicenter randomized trial. They found that balloon catheter extraction was superior to the basket catheter, especially for the removal of four or more stones. We think the results make an important contribution to the current knowledge as well as to the daily practice of endoscopists. However, there are some points that need to be clarified and discussed further.
Brain Abscess and Head Trauma
Authors: Roger C. Duvoisin
Journal: JAMA (1961)

<h3>To the Editor:—</h3> The case of cerebral abscess developing symptoms one day following a minor head injury reported by Drs. Winter and Shoshkes (<i>JAMA</i><b>176</b>:1039 [June 24] 1961) calls for comment on the relationship of the trauma to the abscess. The authors were apparently satisfied that the trauma was etiologically significant, for alternate possibilities were not discussed. However, it seems incredible that such an abscess could have grown within 24 hours of its inception to a size sufficient to produce a hemiparesis. It seems very unlikely to me that the trauma was of any importance, except for the consideration that it might have precipitated or hastened the clinical expression of a previously silent abscess. Possibly the fall in which the patient struck her head was itself the first symptom of the abscess and the immediate result of a then unrecognized hemiparesis. Surely minor trauma cannot so easily be indicted
Association of adjuvant chemotherapy with clinical outcomes in patients treated with neoadjuvant chemoradiation for locally advanced rectal cancer.
Authors: Michael M. Vickers, Jamison Mercer, Aalok Kumar, Gillian Gresham, Rachel Anne Goodwin, Maria Jiang, Patricia A. Tang, Soundouss Raissouni, Erin Diana Powell, Julie A. Price Hiller, Jose Gerard Monzon, Winson Y. Cheung, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2014)

3628 Background: Clinical trial data does not support the routine use of adjuvant chemotherapy (ACT) following neoadjuvant chemoradiation (nCRT) and surgery (Sx) in rectal cancer (Ca). Few studies have included oxaliplatin-based ACT or assessed the benefit in specific pathologic stage (Pstage) subgroups. Methods: Data from patients (pts) with locally advanced rectal Ca who received nCRT and had curative intent Sx from 2005 to 2012 were collected from Tom Baker Cancer Center, Cross Cancer Institute, BC Cancer Agency, Ottawa Hospital Cancer Centre and Dr. H. Bliss Murphy Cancer Centre. The effect of ACT on Time Free of Recurrence (TFR – death without recurrence censored), Disease Free Survival (DFS) and Overall Survival (OS) was assessed using cox proportional hazards model, controlling for age, sex, performance status (PS), circumferential resection margin (CRM), location of tumor, RT dose, Clinical stage (Cstage), Pstage. Results: 1172 pts were included, with a mean age of 61.6 (± 0.33) and a mean follow-up time of 3.8 years (± 0.05). 303 (25.9%) pts received oxaliplatin-based ACT, while 328 (28%) did not receive any ACT and these pts were more likely to be older (65.8 v 65 yrs, p<0.0001), have worse PS (p=0.009), receive lower doses of RT (p=0.0003) and have earlier Cstage (p=0.004) on univariate analysis compared with ACT pts. Univariate analyses for Pstage 0-II were non-significant (NS) for effect of ACT on TFR and DFS. See Table for all pts and Pstage III outcomes controlling for covariates above. Assessment of ACT in high risk v low risk stage II (as in colon Ca) was NS for TFR (p=0.47), DFS (p=0.7) and OS (p=0.7) adjusting for age, PS and CRM. Conclusions: ACT improved clinical outcomes in our retrospective database, however the benefits may be limited to those with Pstage III. Studies are needed to clarify if factors used to stratify stage II colon Ca into high vs. low risk may be applied to estimate recurrence risk in Pstage II rectal Ca. Population TFR (95% CIs) p-value DFS (95% CIs) p-value OS (95% CIs) p-value All pts ACT v no ACT 0.84 (0.59 – 1.18) 0.31 0.63 (0.47 –0.85) 0.002 0.52 (0.36 – 0.75) 0.0004 Pstage III ACT v no ACT 0.6 (0.39 – 0.93) 0.02 0.53 (0.35 – 0.8) 0.002 0.48 (0.29 – 0.79) 0.004